SCHEMBL880437

SCHEMBL880437

O=C1CC(c2cccc(Cl)c2Cl)c2ccc3ccccc3c2N1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.61
ALDH1A1 P00352 5/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
KMT2A Q03164 1/20 0.59
HSD17B10 Q99714 1/20 0.59
TP53 P04637 3/20 0.56
MAPT P10636 2/20 0.54
HTT P42858 1/20 0.54
IDO1 P14902 2/20 0.53
TDP1 Q9NUW8 2/20 0.50
MAPK1 P28482 1/20 0.50
TSHR P16473 1/20 0.48
CYP2A6 P11509 1/20 0.41
MTNR1A P48039 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14450608 1.00 LMNA (0.61) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL880297 0.92 LMNA (0.64) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL10280610 0.88 LMNA (0.59) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL880307 0.86 IDO1 (0.70) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL10280317 0.84 HSD17B10 (0.54) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL880224 0.84 TP53 (0.62) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL880496 0.84 LMNA (0.61) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL15359680 0.82 HSD17B10 (0.62) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL880290 0.82 HSD17B10 (0.62) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10
SCHEMBL880232 0.82 HSD17B10 (0.62) LMNAALDH1A1SMN1; SMN2KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289022-A1 TETRAMERIC ALPHA-SYNUCLEIN AND USE THEREOF BRANDEIS UNIVERSITY (US) 2013-10-31 US disclosed
US-8440705-B2 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2013-05-14 US disclosed
EP-2433634-A2 Compounds, compositions and methods of inhibiting a-synuclein toxicity The Whitehead Institute for Biomedical Research (US) 2012-03-28 EP disclosed
US-20100004277-A1 COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-01-07 US disclosed
US-20100004277-A1 COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004277-A1 COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING GOLT1B, NPC1L1, NPC1 LMNA 3569/4885ALDH1A1 3699/4885SMN1; SMN2 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.